Reconstructing 2500 years of land use history on the Kemel Heath (Kemeler Heide), southern Rhenish Massif, Germany

Die Kemeler Heide im westlichen Hintertaunus ist heute Teil des größten zusammenhängenden Waldgebietes in Hessen mit einer Waldbedeckung von rund 60 %. Bis ins frühe 19. Jahrhundert wurde sie jedoch als Heide genutzt. Mit der vorliegenden Studie wird versucht, die regionale Landnutzungsgeschichte auf der Kemeler Heide mithilfe verschiedenartiger methodischer Ansätze zu rekonstruieren. Eine besondere Berücksichtigung erfahren dabei historische Relikte, die sich im Wald erhalten haben. Zur Rekonstruktion früherer Landnutzungssysteme wurden hochmittelalterliche Ackerraine in drei verschiedenen Wüstungsfluren kartiert und im Hinblick auf ihre Sedimentzusammensetzung und ihr Alter untersucht. Die Datierung derartiger Ackerkolluvien erfolgte erstmals mit mehreren 14C- und einer OSL-Datierung. Ein weiterer Schwerpunkt der Untersuchungen waren frühneuzeitliche Holzkohlemeilerplätze, anhand derer die Artenzusammensetzung der frühneuzeitlichen Wälder rekonstruiert werden konnte. Zusätzlich wurden auch zwei verschiedene Schlackenhalden als Hinterlassenschaften hochmittelalterlicher Eisenverhüttung datiert und die Ergebnisse mit den Sedimentationsraten einer kolluvialen Dellenfüllung verglichen. Dabei konnte nachgewiesen werden, dass die anthropogene Landnutzung auf der Kemeler Heide spätestens während der Eisenzeit begann. Die stärksten Einflüsse erfolgten jedoch erst während des hohen Mittelalters und der frühen Neuzeit. Besonders im Hochmittelalter führte ausgedehnter Ackerbau dazu, dass der Waldanteil weitaus kleiner war als heute. Die meisten Ackerraine stammen daher aus dieser Periode. Während der Neuzeit wurde dagegen vermehrt Heidewirtschaft betrieben.researc

Solving the TTC 2011 Compiler Optimization Case with QVTR-XSLT

In this short paper we present our solution for the Compiler Optimization case study of the Transformation Tool Contest (TTC) 2011 using the QVTR-XSLT tool. The tool supports editing and execution of the graphical notation of QVT Relations languageComment: In Proceedings TTC 2011, arXiv:1111.440

Introducing innovative cellular therapies into the clinic: a 2-year retrospective experience of a chimeric antigen receptor T-cell programme at a single centre in Switzerland

AIM OF THE STUDY Chimeric antigen receptor T (CAR-T) cells are a powerful form of immune-cell therapy for patients with relapsed/refractory B-cell lymphoma and acute B lymphoblastic leukaemia. CAR-T cells have been commercially available in Switzerland since 2018. Because of the complexity and costs of this treatment it is critical to review patient outcomes in real-world settings, to examine whether the promising results from pivotal trials can be reproduced and to identify clinical parameters that determine their efficacy. METHODS Here we present results of a retrospective study analysing outcomes of patients treated with CAR-T cells in a single academic centre in Switzerland during the first two years after commercial approval (BASEC-No. 2020-02271). Cytokine release syndrome (CRS), immune-cell associated neurotoxicity syndrome (ICANS), responses to treatment, ancillary laboratory studies and administrative specifics of CAR-T treatment were examined and are discussed. RESULTS From October 2018 to August 2020 CAR-T cell therapy was evaluated in 34 patients, mostly with relapsed/refractory aggressive B-cell lymphoma (87% had refractory disease). Thirty-one patients underwent leukapheresis. Three of 31 patients (9.6%) died of rapid disease progression before the CAR-T cell product was delivered, two patients were enrolled into a clinical trial, three patients were not given CAR-T cells for other reasons. Ultimately, 23 patients were infused with a commercial CAR-T cell product and included in this analysis. Fourteen (61%) patients received bridging therapy while waiting for a median of 41 days (range 31-62) for delivery of the CAR-T cell product. Toxicity and severe side effects were rare (CRS >3 in 13%, ICANS > grade 3 in 10% of patients), manageable and resolved completely thereafter. The best overall response rate was 65%, with complete responses in 38% of lymphoma patients. At 12 months postinfusion, 61% of patients were alive and 35% progression free. With a median follow-up of 14 months, 13/23 (56%) patients were alive at the time of writing. CONCLUSION CAR-T cell therapy proved to be safe and manageable under adequate hospital conditions. Outcomes resemble results from pivotal trials. The majority of patients was heavily pretreated and refractory at the time of CAR-T cell infusion. Patient selection, time point of leukapheresis, bridging strategies and timing of CAR-T cell infusion may be critical to further improve outcomes

Biobarometer Schweiz 2020 –Teil 1

Biobarometer Schweiz 2020 –Teil 1 Ausführliche Foliensammlung der Ergebnisse

Consommation de bio – évolutions de la demande et contextes

Au cours des dix dernières années, le marché du bio est passé d’un segment de niche à un marché significatif en termes de chiffres d’affaires et de tendances, avec une part de marché de quelque 11 % rapportée au chiffre d’affaires réalisé avec les denrées alimentaires. La consommation de denrées alimentaires bio est de fait très répandue aujourd’hui. De manière générale, en 2020, un ménage suisse a dépensé en moyenne 820 francs en produits bio. Mais quelles sont les raisons pertinentes qui motivent ces achats et comment évolue la consommation de bio ? Quels facteurs favorisent, ou au contraire, freinent la demande en denrées alimentaires bio ? Le présent rapport se propose d’apporter des réponses à ces questions en procédant à une analyse au regard de deux séries indépendantes de données

Consumo di prodotti bio – tendenze nella domanda e contesti

Negli ultimi dieci anni, il mercato dei prodotti alimentari bio si è trasformato da nicchia a impor-tante mercato di smercio e di tendenza con una quota di circa l'11 per cento. Il consumo di alimenti biologici è molto diffuso oggi. Complessivamente, nel 2020 la spesa in prodotti bio di una famiglia svizzera in media si è aggirata attorno a 820 franchi. Ma quali motivazioni d'acquisto sono rilevanti e come sta evolvendo il consumo di prodotti bio? Quali fattori stimolano o frenano la domanda? Basato sul confronto di due rilevamenti di dati indipendenti, questo rapporto ha lo scopo di rispon-dere a queste domande

Bio-Konsum – Nachfragetrends und Hintergründe

Der Markt mit Bio-Lebensmitteln hat sich im letzten Jahrzehnt von einem Nischen- zu einem wichtigen Absatz- und Trendmarkt mit rund 11 Prozent Marktanteil entwickelt. Der Konsum von Bio-Lebensmitteln ist damit heute sehr verbreitet. Insgesamt gab ein Haushalt in der Schweiz 2020 durchschnittlich 820 Franken für Bio-Produkte aus. Doch welche Kaufmotive sind relevant und wie entwickelt sich der Bio-Konsum? Welche Faktoren wirken fördernd oder hemmend auf die Nachfrage nach Bio-Lebensmitteln? Auf der Basis einer Gegenüberstellung von zwei voneinander unabhängigen Datenerhebungen sollen in diesem Bericht Antworten auf diese Fragen geliefert werden

Haploidentical transplant with posttransplant cyclophosphamide vs matched related and unrelated donor transplant in acute myeloid leukemia and myelodysplastic neoplasm

Hematopoietic cell transplantation from haploidentical donors (haploHCT) has facilitated treatment of AML and MDS by increasing donor availability and became more feasible since the introduction of post-transplant cyclophosphamide (ptCY). In our single-center retrospective analysis including 213 patients with AML or MDS, we compare the outcome of haploHCT (n = 40) with ptCY with HCT from HLA-identical MRD (n = 105) and MUD (n = 68). At 2 years after transplantation, overall survival (OS) after haploHCT was not significantly different (0.59; 95% confidence interval 0.44-0.79) compared to MRD (0.77; 0.67-0.88) and MUD transplantation (0.72; 0.64-0.82, p = 0.51). While progression-free survival (PFS) was also not significantly different (haploHCT: 0.60; 0.46-0.78, MRD: 0.55; 0.44-0.69, MUD: 0.64; 0.55-0.74, p = 0.64), non-relapse mortality (NRM) was significantly higher after haploHCT (0.18; 0.08-0.33) vs. MRD (0.029; 0.005-0.09) and MUD (0.06; 0.02-0.12, p < 0.05). Higher NRM was mainly caused by a higher rate of fatal infections, while deaths related to GvHD or other non-relapse reasons were rare in all groups. As most fatal infections occurred early and were bacterial related, one potential risk factor among many was identified in the significantly longer time to neutrophil engraftment after haploHCT with a median of 16 days (interquartile range; 14.8-20.0) vs. 12 days (10.0-13.0) for MRD and 11 days (10.0-13.0) for MUD (p = 0.01)

Distinct and stage-specific contributions of TET1 and TET2 to stepwise cytosine oxidation in the transition from naive to primed pluripotency

Cytosine DNA bases can be methylated by DNA methyltransferases and subsequently oxidized by TET proteins. The resulting 5-hydroxymethylcytosine (5hmC), 5-formylcytosine (5fC), and 5-carboxylcytosine (5caC) are considered demethylation intermediates as well as stable epigenetic marks. To dissect the contributions of these cytosine modifying enzymes, we generated combinations of Tet knockout (KO) embryonic stem cells (ESCs) and systematically measured protein and DNA modification levels at the transition from naive to primed pluripotency. Whereas the increase of genomic 5-methylcytosine (5mC) levels during exit from pluripotency correlated with an upregulation of the de novo DNA methyltransferases DNMT3A and DNMT3B, the subsequent oxidation steps turned out to be far more complex. The strong increase of oxidized cytosine bases (5hmC, 5fC, and 5caC) was accompanied by a drop in TET2 levels, yet the analysis of KO cells suggested that TET2 is responsible for most 5fC formation. The comparison of modified cytosine and enzyme levels in Tet KO cells revealed distinct and differentiation-dependent contributions of TET1 and TET2 to 5hmC and 5fC formation arguing against a processive mechanism of 5mC oxidation. The apparent independent steps of 5hmC and 5fC formation suggest yet to be identified mechanisms regulating TET activity that may constitute another layer of epigenetic regulation